NCT04904302View on ClinicalTrials.gov

Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

May 3, 2022

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Advanced Clear Cell Renal Cell CarcinomaMetastatic Clear Cell Renal Cell CarcinomaStage IV Renal Cell Cancer AJCC v8
Interventions
BIOLOGICAL

Nivolumab

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Sitravatinib

Given PO

Trial Locations (2)

46202

Indiana University Hospital / IU Simon Cancer Center, Indianapolis

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER